A quantitative and robust bioassay that is reflective of the MOA of the drug is a critical component of any…

COVID-19 has been declared a global pandemic by WHO. The disease is transmitted when the SARS-CoV-2 virus infects the respiratory…

Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflamm

GPCRs are privileged drug targets. Approximately 100 receptors still escape from the drug discovery process as they are orphans, without…

Throughout early discovery and particularly for market release, biologic drug candidates require mechanism-of-action (MOA)-based functional, cellul

This webinar, presented by Dr Daniela Cipolletta, Senior Director of Immunology at Seismic Therapeutic, explores how immune checkpoint dysfunction

Protein kinases are critical to many cellular pathways and play a role in several therapeutic areas such as oncology, inflammation,…

Here we will describe InCELL Pulse™, which uses DiscoverX’s Enzyme Fragment Complementation (EFC) technology to overcome these limitations of curre

It is well established that ligand binding can protect proteins from thermal denaturation in a cellular milieu; however, the broad…

Kinase inhibitors often potently inhibit several off-target kinases in biochemical assays. Unfortunately, the relevance of these off-target interac

The webinar focusses on measuring antibody-mediated cell death using DiscoverX’s KILR Bioassays, and how they can be used to measure…

PBMC effector cells have inherent donor variability, reducing their consistency and reproducibility in lot release assays. Antibody-Dependent Cell